Bio-Techne Corp
NASDAQ:TECH

Watchlist Manager
Bio-Techne Corp Logo
Bio-Techne Corp
NASDAQ:TECH
Watchlist
Price: 73.03 USD 0.4%
Market Cap: 11.6B USD
Have any thoughts about
Bio-Techne Corp?
Write Note

Bio-Techne Corp
Cash from Investing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Bio-Techne Corp
Cash from Investing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Investing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Bio-Techne Corp
NASDAQ:TECH
Cash from Investing Activities
-$70.6m
CAGR 3-Years
34%
CAGR 5-Years
-2%
CAGR 10-Years
10%
Thermo Fisher Scientific Inc
NYSE:TMO
Cash from Investing Activities
-$6.2B
CAGR 3-Years
-17%
CAGR 5-Years
-27%
CAGR 10-Years
6%
Danaher Corp
NYSE:DHR
Cash from Investing Activities
-$7.3B
CAGR 3-Years
17%
CAGR 5-Years
-42%
CAGR 10-Years
-22%
Mettler-Toledo International Inc
NYSE:MTD
Cash from Investing Activities
-$103.9m
CAGR 3-Years
28%
CAGR 5-Years
3%
CAGR 10-Years
-1%
Agilent Technologies Inc
NYSE:A
Cash from Investing Activities
-$1.3B
CAGR 3-Years
-19%
CAGR 5-Years
5%
CAGR 10-Years
-19%
IQVIA Holdings Inc
NYSE:IQV
Cash from Investing Activities
-$1.3B
CAGR 3-Years
7%
CAGR 5-Years
-4%
CAGR 10-Years
-24%
No Stocks Found

Bio-Techne Corp
Glance View

Market Cap
11.6B USD
Industry
Life Sciences Tools & Services
Economic Moat
None

Bio-Techne Corp. began its journey with a clear focus: to bridge the gap between biological research and practical applications, a mission that it continues to pursue with zeal. At its core, Bio-Techne operates as a pioneer in the production and distribution of biotechnology products, catering to the needs of the scientific community across the globe. The company specializes in providing essential tools for life sciences research, including proteins, antibodies, and reagents, empowering researchers to explore and innovate in fields ranging from cancer biology to neuroscience. These offerings are developed with meticulous care and a deep understanding of the scientific process, which positions Bio-Techne as a trusted ally to laboratories and research institutions worldwide. The financial heartbeat of Bio-Techne lies in its diverse portfolio, which extends into clinical diagnostics and genomics, segments that are critical in an era of personalized medicine and rapid technological advancement in healthcare. The company's revenue streams are robust, driven by a strategic blend of direct sales and collaborations with major pharmaceutical and biotech companies. Furthermore, Bio-Techne smartly leverages its acquisitions to fortify its market position, enhancing its capabilities and expanding its product lines. This agility and foresight not only enable Bio-Techne to sustain its growth trajectory but also to continually meet the ever-evolving demands of a fast-paced, innovation-driven industry.

TECH Intrinsic Value
57.79 USD
Overvaluation 21%
Intrinsic Value
Price

See Also

What is Bio-Techne Corp's Cash from Investing Activities?
Cash from Investing Activities
-70.6m USD

Based on the financial report for Sep 30, 2024, Bio-Techne Corp's Cash from Investing Activities amounts to -70.6m USD.

What is Bio-Techne Corp's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 10Y
10%

Over the last year, the Cash from Investing Activities growth was 82%. The average annual Cash from Investing Activities growth rates for Bio-Techne Corp have been 34% over the past three years , -2% over the past five years , and 10% over the past ten years .

Back to Top